Medical Simulation Medical Graphic
Medical Animation | MOA | Medical Illustration | Holo 3D | General 3D | Video Game Development | Contact

Biotechnology Animations – Biotechnology Illustrations

Clinical Animations / Trial Animations

Clinical Studies Animated Method of Action Video

Medical Animation Studio produces clinical animations and clinical illustrations.  Custom 3d trail illustrations and clinical illustrations for e learning can also be produced.   Biotechnology animations and biotechnology illustrations created for biotech companies and biotechnology marketing companies.
Biotechnology animated method of action video. 
Dr Nano
New York Hospital Queens seeks volunteers for long-term NIH trial comparing type 2 diabetes treatments
New York Hospital Queens (NYHQ) is looking for volunteers to participate in an ongoing clinical research study designed to determine which of four widely-used FDA-approved diabetes medications...
Results of new drug, ASP8273, show response in patients with treatment-resistant NSCLC
In a second presentation looking at new ways of treating non-small cell lung cancer (NSCLC) that has both the EGFR and T790M mutations, researchers tod the 26th EORTC-NCI-AACR1 Symposium on...
Hepatitis C: Phase III UNITY trials results
Bristol-Myers Squibb Company has announced late-breaking data from the UNITY Trial program investigating a 12-week regimen of its all-oral daclatasvir (DCV) TRIO regimen - a fixed-dose combination...
Melanoma immunotherapy inhibits tumor growth & increases survival
Inovio Pharmaceuticals, Inc. has announced its newest DNA-based cancer immunotherapy targeting melanoma induced a robust and broad immune response in animals and directed cancer-killing T cells...
Preclinical studies of Cardioxyl's HNO prodrugs demonstrate effective treatment of chronic diastolic dysfunction and potential for oral administration
Researchers testing Cardioxyl Pharmaceuticals, Inc. experimental HNO prodrugs presented data demonstrating that HNO improves cardiac function in animal models of diastolic heart failure, and...
Researchers identify biological indicator of response to new ovarian cancer drug
Researchers have found a way of identifying which ovarian cancer patients are likely to respond well to a new anti-cancer drug called rucaparib.
Early results show response to new drug in patients with lymphomas and advanced solid tumours
Patients with B-cell Non-Hodgkin lymphomas and advanced solid tumours have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.
New long-term analyses of Celgene's OTEZLA® (apremilast) in psoriatic arthritis presented at ACR 2014
Celgene Corporation has announced that results from long-term (104-week) efficacy and safety analyses of OTEZLA® (apremilast) from the open-label phase of two PALACE phase III clinical trials...
Results announced from six Phase 3 trials showing that alirocumab significantly reduced LDL cholesterol
Sanofi and Regeneron Pharmaceuticals, Inc. has announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein...
Three drugs may be better than one for certain patients with advanced colorectal cancer
Patients with a form of advanced colorectal cancer that is driven by a mutated version of the BRAF gene have limited treatment options available.
Half of patients do not take meds as prescribed, yet no effective interventions in place
A review examines previous trials aimed at tackling poor patient adherence to meds and finds that studies so far have been poorly designed, yielding 'inconsistent' results.
Data show Vectra DA is better predictor of joint damage in rheumatoid arthritis patients
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., has presented new data that showed Vectra® DA is a better predictor of radiographic progression over two years than...
Results of large cholesterol-lowering/outcomes study revealed at AHA
Merck, known as MSD outside the United States and Canada, has announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints.
Trial results show treatment-resistant advanced non-small cell lung cancer responds to new drug, rociletinib
A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment...
New data from PARADIGM-HF study for heart failure drug LCZ696 released
New data from PARADIGM-HF, the largest-ever heart failure study showed that LCZ696 has the potential to change the course of the disease for patients with HFrEF.
WindowsFlashQuicktime
Request Demo Reel DVD
Related Medical Animation Links

Copyright © 2014
Content Management / Website Design by Tresware